Unpacking the 2026 Guidelines for Acute Pulmonary Embolism: What Interventional Radiologists and Cardiologists Need to Know-Slides: Risk Stratification Scheme for PE, Dr. Piazza

Slides: Risk Stratification Scheme for PE, Dr. Piazza

Pdf Summary

This document reviews evolving approaches to risk stratification in acute pulmonary embolism (PE). It emphasizes that PE is a spectrum of disease, and accurate risk assessment is essential for guiding management, disposition, and use of advanced therapies. Traditional systems, such as the 2019 ESC guidelines, helped classify risk but often grouped together patients with very different prognoses. Newer approaches aim for greater precision by incorporating clinical severity, biomarkers, right ventricular (RV) dysfunction, imaging findings, and clinical phenotypes.<br /><br />The presentation highlights multiple predictors of worse outcomes, including RV enlargement on CT, increased RV/LV ratio, echocardiographic measures of RV strain, TAPSE/PASP ratio, clot burden, and radiomics from dual-energy CT. It also notes emerging work on clustering patients into phenotypic subgroups, suggesting that some intermediate-high-risk patients may have distinct clinical patterns.<br /><br />A major theme is the expanding role of PE response teams (PERTs) in coordinating rapid, individualized care. Future risk stratification is expected to move toward more descriptive clinical categories, serial reassessment, and AI-informed decision support.<br /><br />The 2026 AHA/ACC acute PE guideline introduces a new classification scheme with five categories (A–E), ranging from low to high risk. Asymptomatic patients may be safely discharged, low-severity symptomatic patients may be discharged early, while patients with elevated biomarkers, RV dysfunction, incipient cardiopulmonary failure, or persistent hypotension should be hospitalized. Advanced therapies such as thrombolysis, catheter-based treatment, thrombectomy, or surgery are reasonable in the highest-risk groups. The guideline also recommends PERT use, low-molecular-weight heparin over unfractionated heparin when parenteral anticoagulation is needed, direct oral anticoagulants over vitamin K antagonists when appropriate, extended anticoagulation in selected patients, and follow-up for at least one year to detect chronic thromboembolic disease or persistent symptoms.<br /><br />Overall, the key message is that PE risk stratification is becoming more nuanced, personalized, and operationally integrated into care.

Keywords

acute pulmonary embolism

risk stratification

right ventricular dysfunction

2019 ESC guidelines

2026 AHA/ACC guideline

PERT

biomarkers

CT imaging

thrombolysis

direct oral anticoagulants